MX9708008A - Anticuerpos monoclonales contra vih-1 y vacunas hechas de los mismos. - Google Patents
Anticuerpos monoclonales contra vih-1 y vacunas hechas de los mismos.Info
- Publication number
- MX9708008A MX9708008A MX9708008A MX9708008A MX9708008A MX 9708008 A MX9708008 A MX 9708008A MX 9708008 A MX9708008 A MX 9708008A MX 9708008 A MX9708008 A MX 9708008A MX 9708008 A MX9708008 A MX 9708008A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- present
- monoclonal antibodies
- mixtures
- antibodies against
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 241000699802 Cricetulus griseus Species 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 210000004102 animal cell Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4216—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
- C07K16/4225—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig against anti-HIV Ig
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invencion describe anticuerpos los cuales pueden ser usados para la manufactura de vacunas para la inmunizacion activa y/o pasiva de personas que necesiten de tal tratamiento. La invencion también proporciona anticuerpos monoclonales humanos que son funcionalmente equivalente a los anticuerpos mencionados anteriormente producidos por cualquiera de uno de los linajes celulares CL1 hasta CL6 (depositados en la Coleccion Europea de Cultivos de Células Animales (ECACC) en PHLS en Porton Down, Salisbury, RU). También es una meta de la presente invencion proporcionar linajes de células de hibridoma y/o CHO que producen cualquiera de los anticuerpos descritos y reivindicados aquí. La invencion está dirigida además a mezclas de los anticuerpos de la presente invencion, así como a los métodos de uso de anticuerpos individuales o mezclas de los mismos para la deteccion, prevencion y/o tratamiento terapéutico de las infecciones por VIH-1 in vitro e in vivo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP1995/001481 WO1996033219A1 (en) | 1995-04-19 | 1995-04-19 | Monoclonal antibodies against hiv-1 and vaccines made thereof |
CA002218515A CA2218515C (en) | 1995-04-19 | 1995-04-19 | Monoclonal antibodies against hiv-1 and vaccines made thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9708008A true MX9708008A (es) | 1998-03-31 |
Family
ID=25679733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9708008A MX9708008A (es) | 1995-04-19 | 1995-04-19 | Anticuerpos monoclonales contra vih-1 y vacunas hechas de los mismos. |
Country Status (11)
Country | Link |
---|---|
US (1) | US5911989A (es) |
EP (1) | EP0822941B1 (es) |
AT (1) | ATE219105T1 (es) |
AU (1) | AU2308595A (es) |
BR (1) | BR9510575A (es) |
CA (1) | CA2218515C (es) |
DE (1) | DE69527089T2 (es) |
ES (1) | ES2178672T3 (es) |
MX (1) | MX9708008A (es) |
WO (1) | WO1996033219A1 (es) |
ZA (1) | ZA962629B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60014673T2 (de) * | 1999-08-31 | 2005-02-17 | Asahi Glass Co., Ltd. | Verfahren zum herstellen eines vic-dichlorsäurefluorids |
WO2002072754A2 (en) * | 2001-03-08 | 2002-09-19 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mva expressing modified hiv envelope, gag, and pol genes |
US8623379B2 (en) | 2000-03-02 | 2014-01-07 | Emory University | Compositions and methods for generating an immune response |
US20020106798A1 (en) * | 2000-03-02 | 2002-08-08 | Robinson Harriet L. | DNA expression vectors and methods of use |
US20040105871A1 (en) * | 2000-03-02 | 2004-06-03 | Robinson Harriet L. | Compositions and methods for generating an immune response |
CN1339319A (zh) * | 2000-08-18 | 2002-03-13 | 清华大学 | 一种治疗艾滋病的药物及其制备方法 |
US7591994B2 (en) | 2002-12-13 | 2009-09-22 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
US8658773B2 (en) | 2011-05-02 | 2014-02-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
WO2004033663A2 (en) * | 2002-10-11 | 2004-04-22 | University Of Maryland Biotechnology Institute Off. Of Research Admin./ Tech. Dev. | Carbohydrate-based synthetic vaccines for hiv |
EP1627046A4 (en) * | 2003-05-06 | 2008-02-13 | Scripps Research Inst | DOMAIN EXCHANGE BINDING MOLECULES, METHODS OF USE AND METHODS OF PRODUCTION |
WO2006110831A2 (en) | 2005-04-12 | 2006-10-19 | Duke University | Method of inducing neutralizing antibodies to human immunodeficiency virus |
JP2009545621A (ja) * | 2006-08-02 | 2009-12-24 | ユナイテッド セラピューティクス コーポレーション | ウィルス感染症のリポソーム処置 |
US8956627B2 (en) | 2007-04-13 | 2015-02-17 | Duke University | Method of inducing antibodies to human immunodeficiency virus involving the administration of MPER peptide-liposome conjugates |
US20090252785A1 (en) * | 2008-03-26 | 2009-10-08 | University Of Oxford | Endoplasmic reticulum targeting liposomes |
US20110305700A1 (en) * | 2008-09-05 | 2011-12-15 | Duke University | Anti-lipid antibodies |
WO2010027501A2 (en) * | 2008-09-05 | 2010-03-11 | Duke University | Anti-lipid antibodies |
US20100081575A1 (en) * | 2008-09-22 | 2010-04-01 | Robert Anthony Williamson | Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules |
WO2010033229A2 (en) | 2008-09-22 | 2010-03-25 | Calmune Corporation | Methods and vectors for display of molecules and displayed molecules and collections |
WO2010093395A1 (en) | 2009-02-13 | 2010-08-19 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
KR20120059447A (ko) | 2009-03-27 | 2012-06-08 | 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 | 콜레스테롤 수준 저하 리포좀 |
US20110189183A1 (en) | 2009-09-18 | 2011-08-04 | Robert Anthony Williamson | Antibodies against candida, collections thereof and methods of use |
WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
EP2492279A1 (en) | 2011-02-25 | 2012-08-29 | Laboratorios Del. Dr. Esteve, S.A. | Rapid immunogen selection method using lentiviral display |
RS57397B8 (sr) | 2011-06-10 | 2020-01-31 | Univ Oregon Health & Science | Cmv glikoproteini i rekombinantni vektori |
US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
WO2014028560A2 (en) | 2012-08-14 | 2014-02-20 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
EP2698377A1 (en) | 2012-08-17 | 2014-02-19 | Laboratorios Del. Dr. Esteve, S.A. | Enhanced rapid immunogen selection method for HIV gp120 variants |
KR102536723B1 (ko) | 2012-12-13 | 2023-05-30 | 이뮤노메딕스, 인코오포레이티드 | 개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약 |
WO2017004144A1 (en) | 2015-07-01 | 2017-01-05 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
US10076567B2 (en) | 2013-09-27 | 2018-09-18 | Duke University | MPER-liposome conjugates and uses thereof |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
PL3126383T3 (pl) | 2014-04-03 | 2019-08-30 | Igm Biosciences, Inc. | Zmodyfikowany łańcuch J |
WO2015197919A1 (en) | 2014-06-25 | 2015-12-30 | Glykos Finland Oy | Antibody drug conjugates binding to high-mannose n-glycan |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
CN107735104B (zh) | 2015-06-25 | 2022-05-03 | 免疫医疗公司 | 组合抗hla-dr抗体或抗trop-2抗体与微管抑制剂、parp抑制剂、布鲁顿激酶抑制剂或磷酸肌醇3-激酶抑制剂使癌症治疗结果显著改善 |
CN108463245A (zh) | 2015-09-30 | 2018-08-28 | Igm生物科学有限公司 | 具有修饰的j链的结合分子 |
JP7058213B2 (ja) | 2015-09-30 | 2022-04-21 | アイジーエム バイオサイエンシズ インコーポレイテッド | 改変j鎖を有する結合分子 |
CN108779168A (zh) | 2015-12-05 | 2018-11-09 | 沃迪奥斯大学医院中心 | Hiv结合剂 |
WO2023016488A1 (zh) | 2021-08-13 | 2023-02-16 | 昆山新蕴达生物科技有限公司 | 一种基于微管抑制剂的抗体偶联药物 |
WO2023024949A1 (zh) | 2021-08-24 | 2023-03-02 | 昆山新蕴达生物科技有限公司 | 一种由可断裂连接子偶联的抗体偶联药物 |
WO2023103854A1 (zh) | 2021-12-09 | 2023-06-15 | 昆山新蕴达生物科技有限公司 | 一种亲和力改善的抗体-药物偶联物、其制备方法及应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4761470A (en) * | 1985-12-16 | 1988-08-02 | Merck & Co., Inc. | Immunogenic synthetic peptide capable of eliciting herpes simplex virus neutralizing antibody |
US5087557A (en) * | 1986-06-23 | 1992-02-11 | Genetic Systems Corporation | Human monoclonal antibody to lymphadenopathy-associated virus |
US5245015A (en) * | 1991-04-26 | 1993-09-14 | Tanox Biosystems, Inc. | Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro |
EP0355140B1 (en) * | 1987-11-13 | 1996-03-20 | KATINGER, Hermann | Human monoclonal anti-hiv-i-antibodies |
IL101201A0 (en) * | 1991-03-11 | 1992-11-15 | Idec Pharma Corp | Methods for selecting antibody reagents,anti-idiotype antibodies and aids vaccine formulations |
US5516657A (en) * | 1992-05-11 | 1996-05-14 | Cambridge Biotech Corporation | Baculovirus vectors for expression of secretory and membrane-bound proteins |
CA2096159C (en) * | 1992-05-14 | 2004-07-20 | Hermann Katinger | Peptides that induce antibodies which neutralize genetically divergent hiv-1 isolates |
UA43350C2 (uk) * | 1993-09-11 | 2001-12-17 | Полімун Саіентіфік Іммунобіологіше Форшунг Гмбх | Пептид, який викликає утворення антитіл, що проявляють нейтралізуючу активність відносно штамів та/або ізолятів віл-1 , та/або пригнічують злиття уражених віл-1 клітин, фармацевтичний засіб для утворення антитіл, спосіб отримання пептиду для утворення антитіл, спосіб отримання антитіл, антитіло iga, що проявляє віл-1 нейтралізуючу активність та/або пригнічує злиття уражених віл-1 клітин |
-
1995
- 1995-04-19 AT AT95916676T patent/ATE219105T1/de active
- 1995-04-19 CA CA002218515A patent/CA2218515C/en not_active Expired - Fee Related
- 1995-04-19 AU AU23085/95A patent/AU2308595A/en not_active Abandoned
- 1995-04-19 DE DE69527089T patent/DE69527089T2/de not_active Expired - Lifetime
- 1995-04-19 EP EP95916676A patent/EP0822941B1/en not_active Expired - Lifetime
- 1995-04-19 MX MX9708008A patent/MX9708008A/es unknown
- 1995-04-19 ES ES95916676T patent/ES2178672T3/es not_active Expired - Lifetime
- 1995-04-19 BR BR9510575A patent/BR9510575A/pt not_active Application Discontinuation
- 1995-04-19 WO PCT/EP1995/001481 patent/WO1996033219A1/en active IP Right Grant
- 1995-06-07 US US08/478,536 patent/US5911989A/en not_active Expired - Lifetime
-
1996
- 1996-04-02 ZA ZA9602629A patent/ZA962629B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP0822941A1 (en) | 1998-02-11 |
CA2218515A1 (en) | 1996-10-24 |
ZA962629B (en) | 1997-10-02 |
AU2308595A (en) | 1996-11-07 |
ATE219105T1 (de) | 2002-06-15 |
ES2178672T3 (es) | 2003-01-01 |
DE69527089D1 (de) | 2002-07-18 |
BR9510575A (pt) | 1998-12-15 |
EP0822941B1 (en) | 2002-06-12 |
US5911989A (en) | 1999-06-15 |
CA2218515C (en) | 2008-10-07 |
WO1996033219A1 (en) | 1996-10-24 |
DE69527089T2 (de) | 2003-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9708008A (es) | Anticuerpos monoclonales contra vih-1 y vacunas hechas de los mismos. | |
DE69433013D1 (de) | Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten | |
EP0517815A4 (en) | An igg-1 human monoclonal antibody reactive with an hiv-1 glycoprotein and method of use | |
DK0586002T3 (da) | Monoklonale antistoffer, som genkender epidermisvækstfaktor-receptoren, celler og fremgangsmåder heraf og præparater indeho | |
EP0671927A4 (en) | HUMAN, NEUTRALIZING, MONOCLONAL ANTIBODIES AGAINST THE RESPIRATORY SYNCYTIAL VIRU. | |
CA2310888A1 (en) | Monoclonal human natural antibodies | |
EP1245676A4 (en) | HUMANE MONOCLONAL ANTIBODIES AGAINST THE TGF-BETA II RECEPTOR AND THEIR MEDICAL USE | |
UA111707C2 (uk) | Застосування виділеного анти-tnf-альфа антитіла людини | |
EA200101064A1 (ru) | Лечение раковых заболеваний путем комбинированного введения доцетаксела с рекомбинантными гуманизированными моноклональными анти-her2 антителами | |
DE69626423T2 (de) | Verfahren und zusammensetzung zum rekonformieren multiepitopischer antigene zum anregen einer immunantwort | |
HUP0101160A2 (hu) | Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására | |
ES2194015T3 (es) | Anticuerpos monoclonales humanos neutralizantes del virus de inmunodeficiencia humana. | |
DK0592521T3 (da) | Marv-afledte humane mesenchymal-stamceller og monoklonale antistoffer specifikke for nævnte celler | |
SG161737A1 (en) | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors | |
PT912611E (pt) | Anticorpos monoclonais humanos para o anti-gene de superficie da hepatite b | |
AR003941A1 (es) | Anticuerpos monoclonales humanos neutralizadores de hiv-1 | |
CA2449488A1 (en) | Compositions and methods for treating hyperimmune response in the eye | |
DE3854267D1 (de) | HIV-spezifische monoklonale Antikörper und Hybridome zu ihrer Herstellung. | |
ATE201601T1 (de) | Pharmazeutische zusammensetzungen enthaltend ein neutralisiertes virus, und verwendung derselben | |
NO943653D0 (no) | Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon | |
ES2000615A6 (es) | Procedimiento para la preparacion del anticuerpo monoclonal designado como mak 436-15 del isotipo igg3" | |
ATE207119T1 (de) | Die herstellung von menschlichen, monoklonalen antikörpern, die gegen das oberflächenantigen von hepatitis b aktiv sind | |
TH39342A (th) | โมโนโคลนอลแอนติบอดีต่อ hiv-1 และวัคซีนที่สร้างจากมัน |